Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. You look at survival for patients with ...

Multiple myeloma treatment has advanced with new therapies, increasing life expectancy from under 3 years to over a decade. Health disparities persist, with Black patients facing higher diagnosis ...

The stage of diagnosis can impact survival rates. Patients with stage III multiple myeloma (MM) have an average life expectancy of 29 months, whereas patients with stages I and II disease survive on ...

Your survival rate for multiple myeloma is likely higher in earlier stages. Younger people often have better outcomes due to ...

NUTLEY — Hackensack Meridian Health officially opened its Institute for Multiple Myeloma on Monday evening at the site that was once the Hoffmann-La Roche campus. Not only will the institute support ...

Five FDA authorizations from Aug 2023–Apr 2024 expanded relapsed/refractory options, including bispecific/T-cell engager approaches, stem-cell mobilization, and two CAR T-cell products. Outcomes in ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Joseph Mikhael, MD ...

Pomalyst (pomalidomide) is a brand-name oral capsule prescribed with dexamethasone to treat multiple myeloma in adults who have already tried at least two other treatments and whose cancer has ...

Lindsay Curtis is a health & medical writer in South Florida. She worked as a communications professional for health nonprofits and the University of Toronto’s Faculty of Medicine and Faculty of ...